Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells

Clin Cancer Res (2007) 13 (11): 3413–3422.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy
  • Anna V. Ivanina Foureau
  • David M. Foureau
  • Cody C. McHale
  • Fei Guo
  • Carol J. Farhangfar
  • Kathryn F. Mileham
Cancers (2024) 16 (13): 2475.
Recent Advances in Pyrimidine-Based Drugs
  • Baskar Nammalwar
  • Richard A. Bunce
Pharmaceuticals (2024) 17 (1): 104.
Synthesis and Biological Properties of EGFR-Targeted Photosensitizer Based on Cationic Porphyrin
  • Yulia S. Bortnevskaya
  • Nikita A. Shiryaev
  • Nikita S. Zakharov
  • Oleg O. Kitoroage
  • Margarita A. Gradova
  • Natalia Yu. Karpechenko
  • Alexander S. Novikov
  • Elena D. Nikolskaya
  • Mariia R. Mollaeva
  • Nikita G. Yabbarov
  • Natal’ya A. Bragina
  • Kseniya A. Zhdanova
Pharmaceutics (2023) 15 (4): 1284.
Design, synthesis and evaluation of new pyrimidine derivatives as EGFRC797S tyrosine kinase inhibitors
  • Yu-Ze Mao
  • Xiao-Xiao Xi
  • Hong-Yi Zhao
  • Yin-Liang Zhang
  • San-Qi Zhang
Bioorganic & Medicinal Chemistry Letters (2023) 91: 129381.
Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study
  • Huijuan Wang
  • Ruyue Xing
  • Mengmeng Li
  • Mina Zhang
  • Chunhua Wei
  • Guowei Zhang
  • Yuanyuan Niu
  • Zhiyong Ma
  • Xiangtao Yan
BMC Cancer (2023) 23 (1)
To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
  • Debroop Basu
  • Riya Pal
  • Maitrayee Sarkar
  • Soubhik Barma
  • Sumit Halder
  • Harekrishna Roy
  • Sisir Nandi
  • Asmita Samadder
Current Topics in Medicinal Chemistry (2023) 23 (30): 2877.
First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
  • Yahua Wu
  • Bin Du
  • Chengliu Lv
  • Xiaohui Ji
  • Yanqin Lan
  • Na Yao
  • Yingjiao Zhu
  • Jinhuo Lai
Annals of Medicine (2023) 55 (2)
The study of EGFR-ligand complex electron property relationship with biological activity
  • Prateek Pathak
  • Vladislav Naumovich
  • Maria Grishina
  • Vladimir Potemkin
Journal of Biomolecular Structure and Dynamics (2022) 40 (1): 375.
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI)versusintercalated TKI with chemotherapy forEGFR-mutated nonsmall cell lung cancer
  • Rolof G.P. Gijtenbeek
  • Vincent van der Noort
  • Joachim G.J.V. Aerts
  • Jeske A. Staal-van den Brekel
  • Egbert F. Smit
  • Frans H. Krouwels
  • Frank A. Wilschut
  • T. Jeroen N. Hiltermann
  • Wim Timens
  • Ed Schuuring
  • Joost D.J. Janssen
  • Martijn Goosens
  • Paul M. van den Berg
  • A. Joop de Langen
  • Jos A. Stigt
  • Ben E.E.M. van den Borne
  • Harry J.M. Groen
  • Wouter H. van Geffen
  • Anthonie J. van der Wekken
ERJ Open Research (2022) 8 (4): 00239-2022.
Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
  • Sheng-Jie Sun
  • Jin-Di Han
  • Wei Liu
  • Zhi-Yong Wu
  • Xiao Zhao
  • Xiang Yan
  • Shun-Chang Jiao
  • Jian Fang
World Journal of Clinical Cases (2022) 10 (18): 6069.
Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
  • Geet Madhukar
  • Naidu Subbarao
Current Cancer Drug Targets (2021) 21 (5): 386.
First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  • Qiang Wu
  • Wuxia Luo
  • Wen Li
  • Ting Wang
  • Lin Huang
  • Feng Xu
Frontiers in Oncology (2021) 11
Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells
  • Ebony Nottingham
  • Elizabeth Mazzio
  • Sunil Kumar Surapaneni
  • Shallu Kutlehria
  • Arindam Mondal
  • Ramesh Badisa
  • Stephen Safe
  • Arun K. Rishi
  • Mandip Singh
Journal of Pharmaceutical Analysis (2021) 11 (6): 799.
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
  • Boonyakorn Boonsri
  • Kiren Yacqub-Usman
  • Pakpoom Thintharua
  • Kyaw Zwar Myint
  • Thannicha Sae-Lao
  • Pam Collier
  • Chinnawut Suriyonplengsaeng
  • Noppadol Larbcharoensub
  • Brinda Balasubramanian
  • Simran Venkatraman
  • Isioma U. Egbuniwe
  • Dhanwant Gomez
  • Abhik Mukherjee
  • Supeecha Kumkate
  • Tavan Janvilisri
  • Abed M Zaitoun
  • Thiti Kuakpaetoon
  • Rutaiwan Tohtong
  • Anna M Grabowska
  • David O. Bates
  • Kanokpan Wongprasert
Cancer Research and Treatment (2021) 53 (2): 457.
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
  • Filippo Papini
  • Janani Sundaresan
  • Alessandro Leonetti
  • Marcello Tiseo
  • Christian Rolfo
  • Godefridus J. Peters
  • Elisa Giovannetti
Critical Reviews in Oncology/Hematology (2021) 166: 103454.
Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting
  • Qianqian Wang
  • Wen Gao
  • Fangyan Gao
  • Shidai Jin
  • Tianyu Qu
  • Fan Lin
  • Chen Zhang
  • Jingya Zhang
  • Zhihong Zhang
  • Liang Chen
  • Renhua Guo
BMC Cancer (2021) 21 (1)
Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
  • Debasis Das
  • Jingbing Wang
  • Jian Hong
ChemMedChem (2021) 16 (16): 2459.
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
  • Ruike Gao
  • Ying Zhang
  • Wei Hou
  • Jie Li
  • Guanghui Zhu
  • Xiaoxiao Zhang
  • Bowen Xu
  • Zhe Wu
  • Heping Wang
Trials (2021) 22 (1)
Anti-melanoma potential of two benzoquinone homologues embelin and rapanone - a comparative in vitro study
  • Dagmara Wróbel-Biedrawa
  • Karolina Grabowska
  • Agnieszka Galanty
  • Danuta Sobolewska
  • Paweł Żmudzki
  • Irma Podolak
Toxicology in Vitro (2020) 65: 104826.
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
  • Dantong Sun
  • Yan Zhu
  • Jingjuan Zhu
  • Junyan Tao
  • Xiaojuan Wei
  • Yang Wo
  • Helei Hou
Molecular Medicine (2020) 26 (1)
Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
  • Seung Tae Kim
  • Jung Yong Hong
  • Jeeyun Lee
  • Joon Oh Park
  • Ho Young Lim
  • Won Ki Kang
  • Young Suk Park
Targeted Oncology (2020) 15 (1): 67.
Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
  • Chi Pan
  • Huijie Duan
  • Yinan Wu
  • Chunpeng Zhu
  • Chenghao Yi
  • Yin Duan
  • Demin Lu
  • Cheng Guo
  • Deqi Wu
  • Yanyan Wang
  • Xianhua Fu
  • Jing Xu
  • Yiding Chen
  • Meng Luo
  • Wei Tian
  • Tao Pan
  • Wenhong Xu
  • Suzhan Zhang
  • Jianjin Huang
International Journal of Oncology (2020)
First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients
  • Youngjoo Lee
  • Hyae Young Kim
  • Byung-Ho Nam
  • Geon Kook Lee
  • Heung Tae Kim
  • Ji-Youn Han
  • Hye Jin An
  • Jin Soo Lee
Clinical Lung Cancer (2020) 21 (6): e572.
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
  • Sara Elena Rebuzzi
  • Roberta Alfieri
  • Silvia La Monica
  • Roberta Minari
  • Pier Giorgio Petronini
  • Marcello Tiseo
Critical Reviews in Oncology/Hematology (2020) 146: 102820.
Poly(ester-thioether) microspheres co-loaded with erlotinib and α-tocopheryl succinate for combinational therapy of non-small cell lung cancer
  • Furong Cheng
  • Xinyu Peng
  • Guolong Meng
  • Yuji Pu
  • Kui Luo
  • Bin He
Journal of Materials Chemistry B (2020) 8 (8): 1728.
EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells
  • Arash Poursheikhani
  • Hassan Yousefi
  • Javad Tavakoli-bazzaz
  • Seyed H. Ghaffari
Iranian Biomedical Journal (2020) 24 (6): 365.
Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients
  • Simona Scodes
  • Federico Cappuzzo
Expert Review of Respiratory Medicine (2020) 14 (6): 565.
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
  • James Chih-Hsin Yang
  • Ying Cheng
  • Haruyasu Murakami
  • Pan-Chyr Yang
  • Jianxing He
  • Kazuhiko Nakagawa
  • Jin Hyoung Kang
  • Joo-Hang Kim
  • Rebecca R. Hozak
  • Tuan Stevon Nguyen
  • Wan Li Zhang
  • Sotaro Enatsu
  • Tarun Puri
  • Mauro Orlando
Journal of Thoracic Oncology (2020) 15 (1): 91.
Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
  • Yuqing Lou
  • Jianlin Xu
  • Yanwei Zhang
  • Jun Lu
  • Tianqing Chu
  • Xueyan Zhang
  • Huimin Wang
  • Hua Zhong
  • Wei Zhang
  • Baohui Han
Targeted Oncology (2020) 15 (2): 175.
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
  • Lisheng Xu
  • Qian Qi
  • Yan Zhang
  • Jiadong Cui
  • Ruijuan Liu
  • Yu Li
Lung Cancer (2019) 133: 23.
Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
  • Tianze Liu
  • Lizi Jin
  • Wenjing Lu
  • Hairun Gan
  • Zhidong Lin
  • Miao Chen
  • Jiani Liu
  • Fan Zhang
  • Siyang Wang
  • Hongyu Zhang
  • Wuguo Deng
  • Hongtao Chen
Journal of Experimental & Clinical Cancer Research (2019) 38 (1)
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L)
  • Tatsuo Kimura
  • Tomoya Kawaguchi
  • Yasutaka Chiba
  • Hiroshige Yoshioka
  • Katsuya Watanabe
  • Takashi Kijima
  • Yoshihito Kogure
  • Tetsuya Oguri
  • Naruo Yoshimura
  • Takashi Niwa
  • Takashi Kasai
  • Hidetoshi Hayashi
  • Akira Ono
  • Kazuhisa Asai
  • Hiroshi Tanaka
  • Seiji Yano
  • Nobuyuki Yamamoto
  • Yoichi Nakanishi
  • Kazuhiko Nakagawa
Japanese Journal of Clinical Oncology (2019) 49 (10): 947.
Tailoring the Chemical Modification of Chitosan Hydrogels to Fine-Tune the Release of a Synergistic Combination of Chemotherapeutics
  • John D. Schneible
  • Ankush Singhal
  • Radina L. Lilova
  • Carol K. Hall
  • Andrea Grafmüller
  • Stefano Menegatti
Biomacromolecules (2019) 20 (8): 3126.
Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
  • Ji-Hyun Kwon
  • Kui-Jin Kim
  • Ji Hea Sung
  • Koung Jin Suh
  • Ji Yun Lee
  • Ji-Won Kim
  • Se Hyun Kim
  • Jeong-Ok Lee
  • Jin Won Kim
  • Yu Jung Kim
  • Keun-Wook Lee
  • Jee Hyun Kim
  • Soo-Mee Bang
  • Soyeon Kim
  • Sung-Soo Yoon
  • Jong Seok Lee
Cells (2019) 8 (12): 1538.
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
  • Silvia La Monica
  • Roberta Minari
  • Daniele Cretella
  • Lisa Flammini
  • Claudia Fumarola
  • Mara Bonelli
  • Andrea Cavazzoni
  • Graziana Digiacomo
  • Maricla Galetti
  • Denise Madeddu
  • Angela Falco
  • Costanza Annamaria Lagrasta
  • Anna Squadrilli
  • Elisabetta Barocelli
  • Alessandro Romanel
  • Federico Quaini
  • Pier Giorgio Petronini
  • Marcello Tiseo
  • Roberta Alfieri
Journal of Experimental & Clinical Cancer Research (2019) 38 (1)
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
  • Aubrey L. Miller
  • Samuel C. Fehling
  • Patrick L. Garcia
  • Tracy L. Gamblin
  • Leona N. Council
  • Robert C.A.M. van Waardenburg
  • Eddy S. Yang
  • James E. Bradner
  • Karina J. Yoon
eBioMedicine (2019) 44: 419.
Tumor Inhibition Achieved by Targeting and Regulating Multiple Key Elements in EGFR Signaling Pathway Using a Self‐Assembled Nanoprodrug
  • Bowen Li
  • Xin Xie
  • Zelin Chen
  • Chenyue Zhan
  • Fang Zeng
  • Shuizhu Wu
Advanced Functional Materials (2018) 28 (22)
Targeting EGFR in Lung Cancer: Current Standards and Developments
  • Asunción Díaz-Serrano
  • Pablo Gella
  • Elisabeth Jiménez
  • Jon Zugazagoitia
  • Luis Paz-Ares Rodríguez
Drugs (2018) 78 (9): 893.
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
  • James Chih-Hsin Yang
  • Tony Mok
  • Baohui Han
  • Mauro Orlando
  • Tarun Puri
  • Keunchil Park
Clinical Lung Cancer (2018) 19 (1): 27.
Cell death-based treatment of lung adenocarcinoma
  • Tatiana V. Denisenko
  • Inna N. Budkevich
  • Boris Zhivotovsky
Cell Death & Disease (2018) 9 (2)
First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
  • Shuyun Wang
  • Aiqin Gao
  • Jie Liu
  • Yuping Sun
Cancer Chemotherapy and Pharmacology (2018) 81 (3): 443.
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis
  • Xiaoli Wu
Gene (2018) 643: 74.
Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer
  • Eiji Iwama
  • Yoichi Nakanishi
  • Isamu Okamoto
Expert Review of Anticancer Therapy (2018) 18 (3): 267.
Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients
  • Alessandra Bisagni
  • Maria Pagano
  • Sally Maramotti
  • Francesca Zanelli
  • Martina Bonacini
  • Elena Tagliavini
  • Luca Braglia
  • Massimiliano Paci
  • Andrea Mozzarelli
  • Stefania Croci
  • Jung Weon Lee
PLOS ONE (2018) 13 (4): e0196350.
Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities
  • Shaimaa A. Abdelatef
  • Mohammed T. El-Saadi
  • Noha H. Amin
  • Ahmed H. Abdelazeem
  • Hany A. Omar
  • Khaled R.A. Abdellatif
European Journal of Medicinal Chemistry (2018) 150: 567.
Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
  • Jiadong Cui
  • Yan Zhang
  • Di Su
  • Tao Li
  • Yu Li
Thoracic Cancer (2018) 9 (9): 1156.
Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
  • Young Hak Kim
Journal of Clinical Oncology (2017) 35 (6): 692.
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
  • Antonio Rossi
  • Anna La Salvia
  • Massimo Di Maio
Expert Review of Respiratory Medicine (2017) 11 (3): 171.
Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?
  • Anna La Salvia
  • Emmanuele De Luca
  • Antonio Rossi
  • Massimo Di Maio
Expert Opinion on Pharmacotherapy (2017) 18 (18): 1899.
Efficacy of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer patients during tyrosine kinase inhibitor treatment ⁎
  • Guanzhong Zhang
  • Zhaozhe Liu
  • Tao Han
  • Xiaodong Xie
  • Shunchang Jiao
Oncology and Translational Medicine (2017) 3 (3): 93.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept